Tradipitant Emerging Drug Insight and Market Forecast - 2032

“Tradipitant Emerging Drug Insight and Market Forecast - 2032” report provides comprehensive insights about tradipitant for Atopic Dermatitis (AD) in the seven major markets. A detailed picture of the tradipitant for atopic dermatitis in the 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 -2032 is provided in this report along with a detailed description of the tradipitant for atopic dermatitis. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the tradipitant market forecast analysis for atopic dermatitis in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in atopic dermatitis.

Drug Summary

Tradipitant (VLY-686) is a neurokinin-1 (NK-1) receptor antagonist licensed by Vanda from Eli Lilly and Company in 2012. The NK-1R is expressed throughout different tissues of the body, with major activity found in neuronal tissue. SP and NK-1R interactions in neuronal tissue regulate neurogenic inflammation locally and the pain perception pathway through the CNS. The activation of NK-1R by the natural ligand SP is involved in numerous physiological processes, including the perception of pain, behavioral stressors, cravings and the processes of nausea and vomiting. An inappropriate overexpression of SP, either in nervous tissue or peripherally, could result in pathological conditions such as substance dependence, anxiety, nausea/vomiting and pruritus. An NK-1R antagonist may possess the ability to reduce this over-stimulation of the NK-1R, and as a result, address the underlying pathophysiology of the symptoms in these conditions.

The patent describing tradipitant as a new chemical entity is expected to expire in the United States in June 2029 based on an anticipated Hatch-Waxman patent term extension. Tradipitant is currently in Phase III clinical development for pruritus in AD.

Scope of the Report

The report provides insights into:

• A comprehensive product overview including the tradipitant description, mechanism of action, dosage and administration, research and development activities in atopic dermatitis.
• Elaborated details on tradipitant regulatory milestones and other development activities have been provided in this report.
• The report also highlights the tradipitant research and development activities in atopic dermatitis across the United States, Europe and Japan.
• The report also covers the patents information with expiry timeline around tradipitant.
• The report contains forecasted sales of for atopic dermatitis till 2032.
• Comprehensive coverage of the late-stage emerging therapies for atopic dermatitis.
• The report also features the SWOT analysis with analyst views for tradipitant in atopic dermatitis.

Methodology

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the research team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Tradipitant Analytical Perspective

In-depth Tradipitant Market Assessment

This report provides a detailed market assessment of tradipitant for atopic dermatitis in the seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

Tradipitant Clinical Assessment

The report provides the clinical trials information of tradipitant for atopic dermatitis covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights

• In the coming years, the market scenario for atopic dermatitis is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
• The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence tradipitant dominance.
• Other emerging products for atopic dermatitis are expected to give tough market competition to tradipitant and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of tradipitant in atopic dermatitis.
• This in-depth analysis of the forecasted sales data of tradipitant from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the tradipitant in atopic dermatitis.

Key Questions Answered

• What is the product type, route of administration and mechanism of action of tradipitant?
• What is the clinical trial status of the study related to tradipitant in atopic dermatitis and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the tradipitant development?
• What are the key designations that have been granted to tradipitant for atopic dermatitis?
• What is the forecasted market scenario of tradipitant for atopic dermatitis?
• What are the forecasted sales of tradipitant in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
• What are the other emerging products available and how are these giving competition to tradipitant for atopic dermatitis?
• Which are the late-stage emerging therapies under development for the treatment of atopic dermatitis?

This product will be delivered within 2 business days.